Drugs / Atabecestat
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03587376 | May → Aug 2018 | Alzheimer disease | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 111 trials · 2 met primary | ||||||
| Phase 1 | NCT02611518 | Apr → Jun 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02360657 | Feb → Sep 2015 | Alzheimer disease | Janssen Pharmaceutical K.K. | Completed | Met primary |
| Phase 1 | NCT02355561 | Jan → Mar 2015 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02211079 | Sep → Nov 2014 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02197884 | Jul → Sep 2014 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02152332 | Jul → Oct 2014 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02180269 | Jun → Aug 2014 | — | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1 | NCT01978548 | Dec 2013 → Apr 2015 | Alzheimer disease | Janssen Research & Development, LLC | Completed | Met primary |
| Phase 1 | NCT02260700 | Sep → Nov 2013 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01887535 | May → Dec 2013 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01827982 | Mar → Jul 2013 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02406027 | Jul 2015 → Jun 2018 | Alzheimer disease | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT02260674 | Nov 2014 → Jun 2016 | Alzheimer disease | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT02569398 | Oct 2015 → Dec 2018 | amyloidosis | Janssen Research & Development, LLC | Terminated | Missed primary |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Atabecestat | “Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.” PMID 30134967 ↗ Aug 20183“Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients” PMID 32410694 ↗ May 2020 |
| Known as | JNJ-54861911 | “BACKGROUND: β-Secretase enzyme (BACE) inhibition has been proposed as a priority treatment mechanism for Alzheimer's disease (AD), but treatment initiation may need to be very...” PMID 30134967 ↗ Aug 201810“Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients” PMID 32410694 ↗ May 2020 |
| Known as | JNJ-54861911-AAA | ChEMBL registry synonym — accepted as the source's own label CHEMBL3916243 ↗ |
| Known as | RSC- 385896 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3916243 ↗ |
| Action | Inhibit | “inhibitor of BACE1 activity” PMID 32410694 ↗ May 2020 |
| Modality | Small molecule | — CHEMBL3916243 ↗ |
| Route | Oral | “single oral dose” NCT01827982 ↗ |
| Target | BACE1 | “oral BACE1 inhibitor” PMID 30134967 ↗ Aug 2018 |